|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2009-11-17
|
|
pubmed:abstractText |
This study aims to evaluate the multidrug resistance (MDR) reversal activity by magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4) and 5-bromotetrandrine (BrTet) MDR cell line K562/A02 solitarily or symphysially. The proliferation of K562 and K562/A02 cells and the cytotoxicity on peripheral blood mononuclear cells (PMBCs) were evaluated by MTT assay. Cellular accumulation of daunorubicin (DNR) was analyzed by flow cytometry. Real-time polymerase chain reaction and Western blotting analyses were performed to examine the mRNA and protein levels of mdr1, respectively. The results showed that the combination of MNPs-Fe3O4 and BrTet with effective concentrations significantly increased cytotoxicity against MDR cell line K562/A02. Both BrTet and MNPs-Fe3O4 increased the intracellular DNR accumulation in the K562/A02 cell line, and downregulated the level of mdr1 gene and expression of P-glycoprotein. Furthermore, the combination did not have significant cytotoxicity in PMBCs. We propose that MNPs-Fe3O4 conjugated with DNR and BrTet probably have synergetic effects on MDR reversal.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-14666379,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-15237424,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-15350777,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-15378274,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-15494300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-15543372,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-15549214,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-15736412,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-15958579,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-16330661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-16779701,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-16786442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-17385015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-18227410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-18686787,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-2924316,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-6467192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-7902728,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19918367-7964963
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ABCB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Benzylisoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/Daunorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Ferumoxytol,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/bromotetrandrine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1178-2013
|
|
pubmed:author |
pubmed-author:ChenBao-anBA,
pubmed-author:ChenNingnaN,
pubmed-author:ChenWenjiW,
pubmed-author:ChengJianJ,
pubmed-author:DingJiahuaJ,
pubmed-author:GaoChongC,
pubmed-author:GaoFengF,
pubmed-author:HawW WWW,
pubmed-author:LiXiaomaoX,
pubmed-author:LiuLijieL,
pubmed-author:SongHuihuiH,
pubmed-author:SunXinchenX,
pubmed-author:SunYunyuY,
pubmed-author:WangXuemeiX,
pubmed-author:WuWeiweiW,
pubmed-author:XiaGuohuaG,
pubmed-author:XuCuirongC,
pubmed-author:XuWenlinW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
209-16
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19918367-Antibiotics, Antineoplastic,
pubmed-meshheading:19918367-Base Sequence,
pubmed-meshheading:19918367-Benzylisoquinolines,
pubmed-meshheading:19918367-Cell Survival,
pubmed-meshheading:19918367-Daunorubicin,
pubmed-meshheading:19918367-Down-Regulation,
pubmed-meshheading:19918367-Drug Resistance, Multiple,
pubmed-meshheading:19918367-Drug Resistance, Neoplasm,
pubmed-meshheading:19918367-Drug Synergism,
pubmed-meshheading:19918367-Ferumoxytol,
pubmed-meshheading:19918367-Genes, MDR,
pubmed-meshheading:19918367-Humans,
pubmed-meshheading:19918367-K562 Cells,
pubmed-meshheading:19918367-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19918367-Magnetics,
pubmed-meshheading:19918367-Metal Nanoparticles,
pubmed-meshheading:19918367-Nanomedicine,
pubmed-meshheading:19918367-P-Glycoprotein,
pubmed-meshheading:19918367-RNA, Messenger,
pubmed-meshheading:19918367-RNA, Neoplasm
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells.
|
|
pubmed:affiliation |
Department of Hematology, The Affiliated Zhongda Hospital, Southeast University, Nanjing 210009, People's Republic of China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
